According to lead author Shivesh Punit of The Saban Research Institute of CHLA, discovering that tumor necrosis factor receptor 2 (TNFR2) mitigates inflammation in mice was surprising, given that therapies that block tumor necrosis factor (TNF) are the primary treatments for individuals with IBD.
“Understanding this mechanism allows us to target new therapeutic approaches for patients who don’t respond to current therapies,” said principal investigator Brent Polk, MD, who was senior author on this study. Polk is a pediatric gastroenterologist and director of The Saban Research Institute of Children’s Hospital Los Angeles, and is also professor and chairman of pediatrics at the Keck School of Medicine of the University of Southern California.
An autoimmune disorder that causes inflammation of the intestinal tract, IBD is a broad term that includes ulcerative colitis and Crohn’s disease. Characterized by severe gastrointestinal symptoms that get worse over time, IBD negatively affects quality of life and increases risk of colon cancer. In the United States, more than one million people are living with IBD with a cost of treatment of over one billion dollars each year.
Currently, there is no cure for IBD. For patients with moderate to severe disease, one current therapy acts to blocks TNF. Recent research suggests there are various conditions that lead to the disease including a microbial imbalance in the gut, dysregulated immunity and alterations in the epithelial cells that line the intestinal tract. Although anti-TNF medications represent a significant breakthrough in treatment, they are effective in only one third of individuals suffering from IBD.
In the current study, investigators examined the role of TNFR2 in mice with IBD. Biological activity of TNF is mediated by two cell surface receptors—TNFR1 and TNFR2. TNFR2 is located primarily on immune cells and during inflammation increases in the intestinal epithelial cells. When the investigators blocked this receptor–mimicking the effect of anti-TNF treatment–they noted an increase in severity and decrease in time to onset of colitis. To verify that the effect was mediated by TNFR2, they performed bone marrow transfers, and found that mice receiving the TNFR2-deficient bone marrow developed severe disease.
The investigators also noted that loss of TNFR2 increased cytotoxic CD8 T-cells—cells known for playing an important role in immune defense. When the investigators specifically inhibited CD8 cells, IBD resolved. They also showed that loss of TNFR2 on CD8 cells alone worsened IBD. These observations led the investigators to conclude that CD8 T-cells worsen IBD in this model, and that TNFR2 alleviates IBD by inhibiting these cells.
Additional contributors to the study include Philip E. Dube, Cambrian Y. Liu and Nandini Girish, of The Saban Research Institute of Children’s Hospital Los Angeles and the Keck School of Medicine of the University of Southern California; and M. Kay Washington, Vanderbilt University. Funding was provided in part by the National Institutes of Health R01DK056008, R01DK54993 and P30DK058404, the Canadian Institutes of Health Research, the Crohn’s and Colitis Foundation of America, and the California Institute for Regenerative Medicine (CIRM).
About Children’s Hospital Los Angeles
Children’s Hospital Los Angeles has been named the best children’s hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children’s Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children’s Hospital is also one of America’s premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit CHLA.org. Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog at http://researchlablog.org/.
Media contact: Ellin Kavanagh, email@example.com
323-361-8505 or 323-361-1812